The U.S. Food and Drug Administration (FDA) has announced it will permit 20 Zyn nicotine pouch products to advertise that using them instead of cigarettes reduces the risk of serious health conditions, including mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. This decision is a major victory for Philip Morris International, the parent company of Zyn manufacturer Swedish Match, which has consistently argued for the need to provide adult smokers with accurate information about the relative risks of different nicotine products.
FDA scientists supported this marketing claim, stating that "the totality of the evidence" presented during a public meeting in January backed it. The FDA's acting director of the Center for Tobacco Products, Bret Koplow, emphasized that the review process ensures adult users receive clear, science-based information to make informed choices. This move signals the FDA's recognition of the harm-reduction potential of Zyn products, despite concerns raised by critics regarding their appeal to young people and potential cardiovascular effects.
Zyn is a market leader in nicotine pouches, with sales exceeding $3.24 billion last year, accounting for over two-thirds of the market, according to Nielsen data analyzed by Goldman Sachs. While less than 1% of U.S. adults use nicotine pouches, it is the fastest-growing segment of the tobacco market. Although the FDA acknowledges that the science is accurate in suggesting Zyn is a safer alternative for smokers, independent experts and anti-tobacco groups have raised questions about long-term studies on Zyn users, whether the new marketing language will effectively encourage smokers to switch, and the risk of underage usage, especially given the products' flavors and discreet nature.
Philip Morris International previously gained a similar reduced-risk claim for its snus product in 2019, though adoption by U.S. smokers has been modest. Company executives believe the new Zyn marketing language will increase switching from cigarettes. The FDA's decision aims to provide adult smokers with information about lower-risk nicotine alternatives, even as it balances that goal with the need to prevent youth initiation.
